An­thos to stop fac­tor XI tri­al in atri­al fib­ril­la­tion ear­ly af­ter 'over­whelm­ing ben­e­fit'

An­thos Ther­a­peu­tics an­nounced Mon­day morn­ing that it is stop­ping a Phase II study of its next-gen­er­a­tion an­ti­co­ag­u­lant abelacimab in atri­al fib­ril­la­tion as a re­sult of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER